Clinical trials: Locally Advanced Gastric Cancer
Esophageal Cancer, Gastric Cancer
Erlotinib in Treating Patients With Locally Advanced or Metastatic Stomach Cancer or Gastroesophageal Junction Cancer
RATIONALE: Biological therapies such as erlotinib may interfere with the growth of tumor cells and slow the growth of the tumor.
- Trial name
- NCT00032123
- Testing
- erlotinib hydrochloride
- Where
- 107 sites in United States, Canada
- Sponsor
- SWOG Cancer Research Network
Uterine Cervical Neoplasms, Surgery
Gastric-type Endocervical Adenocarcinoma: a Population-based Cohort Study
This study aims to collect data of patients with Gastric-type Endocervical Adenocarcinoma from the SEER database, analyze the related prognostic factors and treatment patterns of Gastric-type Endocervical Adenocarcinoma, and…
- Conditions
- Uterine Cervical Neoplasms, Surgery, Therapy, Locally Advanced Cervical Carcinoma
- Trial name
- NCT06897306
- Testing
- surgery
- Where
- China
- Volunteers
- 317 people
- Sponsor
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Gastric Cancer
CT Body Composition Enhances Survival Risk Stratification
Gastric carcinoma remains the fifth most common malignancy and the second leading cause of cancer-related mortality worldwide. For patients with locally advanced disease, standard treatment includes radical gastrectomy followed…
- Trial name
- NCT07109271
- Where
- Taiwan
- Volunteers
- 227 people
- Sponsor
- Chang Gung Memorial Hospital
Gastric Cancer
Multivisceral Resections for Locally Advanced Gastric Cancer
The goal of this observational study is to assess whether the postoperative course and survival of patients subject to multivisceral resections for locally advanced gastric cancer (cT4b) were affected by the extent of surgery.
- Trial name
- TOCCATA (NCT06103435)
- Testing
- Extent od surgical resection
- Where
- Poland
- Volunteers
- 1,476 people
- Sponsor
- Jagiellonian University
Gastric (Cardia, Body) Cancer, Stomach Adenocarcinoma
Neoadjuvant Nab-Paclitaxel Plus Oxaliplatin, S-1, and Sintilimab in Early-Onset Resectable Gastric Cancer
This study aims to evaluate the effectiveness and safety of a preoperative treatment (called neoadjuvant therapy) combining four drugs-nab-paclitaxel, oxaliplatin, S-1, and sintilimab-for patients with locally advanced…
- Conditions
- Gastric (Cardia, Body) Cancer, Stomach Adenocarcinoma, Locally Advanced
- Trial name
- YOUNG-NEOS (NCT07018063)
- Testing
- nab-paclitaxel, oxaliplatin, S-1
- Where
- China
- Volunteers
- 35 people
- Sponsor
- zhoujing
Gastric Cancer
Surgery for Obstructed Gastric Carcinoma
The goal of this clinical trial is to find the best treatment for obstructed gastric carcinoma in gastric cancer patients. It will include all patients with obstructed gastric cancer with different ages and sex who consented to…
- Trial name
- NCT07435025
- Testing
- palliative gastric resection, palliative bypass
- Where
- Egypt
- Volunteers
- 63 people
- Sponsor
- Zagazig University
Gastric Cancer
A Benefit Population Atlas of nICT Versus nCT for LAGC
The purpose of this observational study is to evaluate the impact of different neoadjuvant therapies on patients with locally advanced gastric cancer.
- Trial name
- NCT07098104
- Testing
- Immunotherapy
- Where
- China
- Volunteers
- 291 people
- Sponsor
- Cheng Chen
Cancer, Sarcoma
EBNK-001 Allogeneic NK Cells With Low-Dose IL-15 ± Pembrolizumab in Advanced Solid Tumors
This Phase 1/2 study evaluates the safety, tolerability, and preliminary anti-tumor activity of EBNK-001 (allogeneic NK cells) given after lymphodepleting cyclophosphamide/fludarabine (CY/FLU) and supported with low-dose IL-15…
- Conditions
- Cancer, Sarcoma, Leukaemia, Breast Cancer (Locally Advanced or Metastatic)
- Trial name
- EBNK-ST-001 (NCT07410676)
- Testing
- EBNK-001 + IL-15 + Pembrolizumab
- Where
- China
- Volunteers
- 83 people
- Sponsor
- Essen Biotech
Colorectal Neuroendocrine Tumor G1, Gastric Neuroendocrine Tumor G1
Octreotide Acetate and Recombinant Interferon Alfa-2b or Bevacizumab in Treating Patients With Metastatic or Locally Advanced, High-Risk Neuroendocrine Tumor
This randomized phase III trial studies octreotide acetate and recombinant interferon alfa-2b to see how well it works compared to octreotide acetate and bevacizumab in treating patients with high-risk neuroendocrine tumors that…
- Conditions
- Colorectal Neuroendocrine Tumor G1, Gastric Neuroendocrine Tumor G1, Neuroendocrine Neoplasm, Neuroendocrine Tumor
- Trial name
- NCT00569127
- Testing
- Bevacizumab, Laboratory Biomarker Analysis, Octreotide Acetate
- Where
- 493 sites in United States
- Volunteers
- 427 people
- Sponsor
- National Cancer Institute (NCI)
Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or Cancer, Locally Advanced Unresectable Gastric Adenocarcinoma or Cancer
A Study to Observe the Safety of VYLOY (Zolbetuximab) in People in South Korea With Gastric or Gastroesophageal Junction Cancer.
This study is for people in South Korea who have cancer in or around the stomach (gastric cancer) or cancer where the food pipe (esophagus) joins the stomach, called gastroesophageal junction (GEJ) cancer.
- Conditions
- Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or Cancer, Locally Advanced Unresectable Gastric Adenocarcinoma or Cancer, Metastatic Gastric Adenocarcinoma or Cancer, Metastatic Gastroesophageal Junction (GEJ) Adenocarcinoma
- Trial name
- NCT06902545
- Testing
- zolbetuximab
- Where
- 15 sites in South Korea
- Volunteers
- 377 people
- Sponsor
- Astellas Pharma Korea, Inc.
Esophageal Cancer, Gastric Cancer
Combination Chemotherapy Followed by Surgery and Intraperitoneal Chemotherapy in Treating Patients With Locally Advanced Stomach Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Giving chemotherapy drugs in different ways may kill more tumor cells.
- Trial name
- NCT00006038
- Testing
- cisplatin, docetaxel, floxuridine
- Where
- United States
- Sponsor
- Memorial Sloan Kettering Cancer Center
Locally Advanced Unresectable or Metastatic Gastric Cancer
A Long-term Follow-up Study of Subjects Enrolled in Clinical Trials of Cadonilimab (AK104)
This is an observational and non-interventional clinical study that only collects long-term follow-up data of the subjects. As the world's first approved PD-1/CTLA-4 bispecific antibody for marketing, Cadonilimab may confer…
- Trial name
- NCT07547787
- Where
- China
- Volunteers
- 610 people
- Sponsor
- Akeso
Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8
Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid Tumors
This phase I/II trial tests the safety and tolerability of an experimental personalized vaccine when given by itself and with pembrolizumab in treating patients with solid tumor cancers that have spread to other places in the…
- Conditions
- Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Anatomic Stage IIIB Breast Cancer AJCC v8, Anatomic Stage IIIC Breast Cancer AJCC v8
- Trial name
- PNeoVCA (NCT05269381)
- Testing
- Cyclophosphamide, Neoantigen Peptide Vaccine, Pembrolizumab
- Where
- United States
- Volunteers
- 138 people
- Sponsor
- Mayo Clinic
Locally Advanced Gastric/Gastroesophageal Junction Adenocarcinoma
Efficacy and Survival Analysis of Perioperative Treatment of Locally Advanced Gastric or Gastroesophageal Junction Cancer
This study is a single-center, retrospective cohort study. The purpose is to evaluate different perioperative treatment options on the efficacy and survival prognosis of locally advanced GC/GEJC, clarify whether the tumor…
- Trial name
- GC/GEJC (NCT07429318)
- Testing
- Chemo only, Immunochemotherapy
- Where
- China
- Volunteers
- 300 people
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Patients With Locally Advanced Carcinoma of the Stomach and Oesophagogastric Junction
Radiomics-based Models for the Prediction of Pathological Response to Neoadjuvant Therapy in Gastric and Gastroesophageal Cancer
Identifying predictors of response to neoadjuvant therapy in gastric and gastro-oesophageal cancer early in the history of the disease would ensure optimal treatment planning.
- Trial name
- RADI-S (NCT06044961)
- Testing
- CT scan
- Volunteers
- 80 people
- Sponsor
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Gastric Cancer (Diagnosis), TNM Staging
Multicenter Study of Clinical-Pathological Correlation in cT2N0 Gastric Cancer and Its Prognostic Implications
In gastric cancer, accurate preoperative staging of patients with T2N0 disease remains challenging. Correct assessment of tumor depth and lymph node involvement is particularly important in this subgroup, as treatment strategies…
- Conditions
- Gastric Cancer (Diagnosis), TNM Staging, Perioperative Treatment in Subjects With Locally Advanced Resectable Gastric Cancer or Gastroesophageal Junction Cancer, Gastric Surgery
- Trial name
- NCT07842549
- Where
- Spain
- Volunteers
- 1,024 people, healthy volunteers welcome
- Sponsor
- Hospital of Navarra